Wells Fargo analyst Yanan Zhu maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) yesterday and set a price target of ...

ADAP Pre-market open on 3/20/25, Adaptimmune (NASDAQ:ADAP) provided a business update for 4Q24 (in lieu of financial results for the quarter/full year to be released in conjunction with the company’s ...

Scotiabank analyst George Farmer lowered the firm’s price target on Adaptimmune (ADAP) to $1.40 from $3.15 and keeps an Outperform rating on ...

Adaptimmune (NASDAQ:ADAP) is scheduled to announce Q4 earnings results on Thursday, March 20th, before market open. The consensus EPS Estimate is -$0.15 (-275.0% Y/Y) and the consensus Revenue ...

StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Thursday. The firm issued a buy rating on the biotechnology company’s ...

Every investor in Adaptimmune Therapeutics plc (NASDAQ:ADAP) should be aware of the most powerful shareholder groups. We can see that retail investors own the lion's share in the company with 50% ...

Short interest in Adaptimmune Therapeutics PLC (NASDAQ:ADAP) increased during the last reporting period, rising from 5.76M to 6.88M. This put 4.03% of the company's publicly available shares short.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.